nipradilol

Also Known As:

3,4-dihydro-8-(2-hydroxy-3--isopropylaminopropoxy)-3-nitroxy-2H-1-benzopyran; K 351; K-351; 2H-1-Benzopyran-3-ol, 3,4-dihydro-8-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, 3-nitrate

Networked: 71 relevant articles (7 outcomes, 19 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Amino Alcohols: 20
    - Propanolamines: 4
      - nipradilol: 71
- Alcohols: 595
  - Amino Alcohols: 20
    - Propanolamines: 4
      - nipradilol: 71
  - Propanols: 3
    - Propanolamines: 4
      - nipradilol: 71

Experts

1.	Araie, Makoto: 6 articles (03/2011 - 01/2006)
2.	Kitazawa, Yoshiaki: 5 articles (07/2010 - 01/2006)
3.	Shirato, Shiroaki: 3 articles (07/2010 - 01/2006)
4.	Azuma, Ikuo: 3 articles (09/2008 - 01/2006)
5.	Masuda, Kanjiro: 3 articles (09/2008 - 01/2006)
6.	Nipradilol-Timolol Study Group: 2 articles (07/2010 - 07/2008)
7.	Ohashi, Yasuo: 2 articles (07/2010 - 07/2008)
8.	Yamazaki, Yoshio: 2 articles (07/2010 - 07/2008)
9.	Kanno, Mikiko: 2 articles (01/2006 - 01/2006)
10.	Ogawa, Nobuya: 2 articles (01/2006 - 01/2006)

Related Diseases

1.	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 05/01/1996 - "This study investigated the therapeutic efficacy of a new beta-blocker, nipradilol, a non-selective agent with vasodilating activity, for the treatment of idiopathic dilated cardiomyopathy (DCM). " 05/01/1996 - "Effect of a new beta-blocker, nipradilol, on cardiac function and neurohumoral factors in idiopathic dilated cardiomyopathy." 01/01/1995 - "This study investigated the therapeutic efficacy of two different beta-blockers, metoprolol (beta 1-selective) and nipradilol (nonselective) for the treatment of idiopathic dilated cardiomyopathy (DCM). " 04/01/1994 - "MIBG-myocardial SPECT was performed on patients with dilated cardiomyopathy (DCM) undergoing treatment with beta blocker (Nipradilol). "
2.	Myocardial Infarction 06/01/1997 - "These results suggest that chronic treatment of nipradilol attenuated left ventricular cavity dilation after myocardial infarction and improved cardiac performance." 03/01/2002 - "Nipradilol can prevent left ventricular systolic and diastolic dysfunction after myocardial infarction in rats." 06/01/1997 - "We determined whether chronic treatment with nipradilol, a beta-blocker with vasodilating action, reduces left ventricular cavity dilation (LV remodeling) following myocardial infarction and improves cardiac performance. " 10/01/1992 - "The effect of nipradilol on hemodynamics at rest and during exercise with a multi-stage bicycle ergometer in supine position was studied in 8 male patients suffering from angina pectoris with old myocardial infarction. " 10/01/1992 - "Effect of nipradilol on cardiovascular hemodynamics during exercise in angina pectoris with old myocardial infarction."
3.	Hypertension (High Blood Pressure) 10/01/2000 - "These results suggest that exogenous NO from nipradilol reduces the endothelial dysfunction caused by hypertension without changing the blood pressure." 03/01/1986 - "It is proposed that nipradilol may be beneficial for the treatment of hypertension and coronary heart disease." 03/01/2004 - "Nipradilol may act as a nitric oxide inducer from HASMC and suspected to work as a supplement to mitigate the impaired endothelial cell function caused by hypertension." 10/01/2000 - "To study the influence of exogenous nitric oxide(NO) on endothelial dysfunction produced by hypertension, we administered a non-depressor dose of nipradilol to two-kidney, one-clip renovascular hypertensive rats(2K1C). " 12/01/1985 - "The hypertension and the hypotension produced by nipradilol and arotinolol persisted even in the presence of propranolol and prazosin or propranolol and yohimbine."
4.	Tremor (Tremors) 11/01/1999 - "These results coupled with evidence that nipradilol does not penetrate the blood-brain barrier indicate that nipradilol exerts an anti-tremor action by blocking peripheral beta2-adrenoceptors." 11/01/1996 - "Treatment of essential and parkinsonian tremor with nipradilol." 10/01/1996 - "Although 1.0 mg/kg nipradilol significantly reduced the tremor, further inhibition of the tremor was not obtained with dosages up to 2.5 mg/kg of the drug. " 11/01/1996 - "Improvement of tremor appeared within 2 or 4 weeks after the start of nipradilol therapy, and the efficacy rate, defined as "moderately effective" or over, was 42.5% in all 40 patients, while that defined as "slightly effective" or over was 87.5%. " 10/01/1996 - "In conclusion, nipradilol was effective for suppressing oxotremorine-induced tremor, as were other beta-blockers."
5.	Essential Hypertension 07/01/1995 - "Efficacy of long-term treatment with nipradilol, a nitroester-containing beta-blocker, in patients with mild-to-moderate essential hypertension." 07/01/1995 - "The effects of long-term treatment with nipradilol, a nitroester-containing beta-blocker, on casual and 24-hour blood pressures were studied in 70 patients with mild-to-moderate essential hypertension. " 07/01/1995 - "These results suggest that nipradilol is a safe and useful long-term antihypertensive drug in both young and older patients with mild-to-moderate essential hypertension. " 10/01/1998 - "Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension."

Related Drugs and Biologics

1.	Metoprolol (Toprol-XL)
2.	Oxotremorine
3.	DNA (Deoxyribonucleic Acid)
4.	Ophthalmic Solutions (Eye Drops)
5.	Propranolol (Inderal)
6.	Nitric Oxide (Nitrogen Monoxide)
7.	Adrenergic beta-Antagonists (beta-Adrenergic Blocking Agents)
8.	Timolol (Blocadren)
9.	Retinaldehyde (Retinal)
10.	Nitroglycerin (Dynamite)

Related Therapies and Procedures

1.	Therapeutics
2.	Ligation
3.	Surgical Instruments (Clip)
4.	Oral Administration
5.	Intravenous Administration